Munch-a-Biotech Today Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (808)	1/22/2000 4:23:00 PM
From: scaram(o)uche	Read Replies (2) of 3158

>> Immediate saving of the $2 billion dollar break up fee. << Guffaw. Yes!! >> Not saying this is wise or good for the development of new drugs. Think many posters will not like the idea and the market apparently thinks it's a bad idea for P & G. << I actually think that mega-mergers in pharma are going to be great for the sector. The more these mergers occur, the more levels between the bench scientist and a "yes, go ahead" from management. Now that our companies (read "MLNM et al.") have cash and strong currency, this bureaucratic mess just increases the chances that they can run through this wide hole and break free for a very long run. And, for a company like P&G, it would get even better..... wandering aimlessly in a field that, while not new to them, is certainly confusing. This would place ex-Genetics Institute management, now largely heading Wyeth, with significant influence over the direction of research at REGN? Would be a definite plus in terms of guidance/prioritization, but I can't imagine it being construed as an overall positive.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next